Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →An analysis of 855 wearable microfluidic sweat-sensing patent records: filing trends from 2017 to 2026, assignee concentration, IPC technology composition, and where claim space remains open.
Filing growth = 2021 (60 records) → 2024 (77); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 855 records in scope (CR5), not the ranked leaders only.
Wearable microfluidic sweat sensing sits at the intersection of skin-contact diagnostics, microfluidic channel design, and biosensor chemistry. The 855 patent records in scope, filed between 2015 and the 2026 data cut-off, cover devices that collect sweat through microchannels on or under the skin and analyze it for glucose, electrolytes, hydration markers, and other analytes without a needle. The field spans everything from adhesive patches to full-band wearables, and increasingly ties sensing output into informatics and machine-learning layers rather than treating the sensor as a standalone readout.
Filing activity has grown steadily rather than exploded, with technology claims heavily weighted toward diagnostic-hardware and material-analysis subclasses. Newer filings increasingly combine 3D-printed fabrication, multimodal sensing, and on-device inference, a direction the most recent representative filing in this dataset illustrates directly.
Across the 855 records in scope, filing activity and subclass composition show where sweat-sensing patent activity has concentrated and where it has spread thin.
Filings rose from 107 in 2017 to a peak of 124 in 2025, with 2021-to-2024 filings up 28% (60 to 77). 2025 and 2026 figures will still rise as publication catches up with filing, so the most recent years understate real activity.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
A61B diagnosis-and-surgery claims cover 78.1% of the 855 records, far ahead of G01N material-analysis claims at 33.5%. Because records can carry multiple IPC codes, these shares sum past 100% and should be read as overlap, not as a partition of the field.
Shares are the percentage of the 855 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about wearable microfluidic sweat sensing patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaSystems and methods for a wearable system that monitors various biomarkers with a 3D-printed wearable electronic skin. The epidermal wearable microfluidic electronic skin may be composed of a combination of multidimensional nanomaterials, polymers, and hydrogels, integrated with sensors, electrodes, microfluidics, and a processor to collect and analyze molecular biomarkers of biofluid samples on the user's skin while simultaneously assessing physiological status.Filed by California Institute of Technology, published 2025-02-27 — illustrates the current frontier of multimodal, ML-integrated sweat-sensing claims.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20060004271A1 | Devices, methods, and kits for non-invasive glucose measurement | 475 |
| 2 | US20150335288A1 | Modular physiologic monitoring systems, kits, and methods | 471 |
| 3 | US20100268056A1 | Washable wearable biosensor | 331 |
| 4 | US20030060693A1 | Apparatus and method for quantification of tissue hydration using diffuse reflectance spectroscopy | 258 |
| 5 | US20140135592A1 | Health band | 205 |
| 6 | US20070027383A1 | Patches, systems, and methods for non-invasive glucose measurement | 191 |
| 7 | US20070179371A1 | Patches, systems, and methods for non-invasive glucose measurement | 177 |
| 8 | WO2014193999A2 | Biomarker methods and compositions | 152 |
| 9 | US20190290172A1 | Systems and methods for food analysis, personalized recommendations, and health management | 144 |
| 10 | US20170325724A1 | Non-invasive and wearable chemical sensors and biosensors | 126 |
Ranked by citation count within the 855-record corpus; citation counts favor older records and should be read as influence, not current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Four figures from the dataset that change how a filing or design-around strategy should be built.
The leader alone holds 44 records, and the top 5 together reach 22.6% of the 855 records in scope. That leaves the bulk of the field, including the top 10's remaining share up to 36.5%, spread across a long tail of smaller filers.
Filings climbed from 60 in 2021 to 77 in 2024, and the trend peaks at 124 in 2025 — though 2025-26 figures are still filling in given an 18-month publication lag, so treat them as a floor, not a ceiling.
A61B (diagnosis and surgery) appears in 78.1% of records, dwarfing every other subclass. G01N material-analysis claims follow at 33.5%, marking the two densest zones of prior art to search before drafting.
A61M (devices for body fluids) sits at just 2.9% of records, with A61N electrotherapy close behind at 3.4%. Both are candidates for closed-loop sensing-plus-actuation claims that avoid the densest prior art.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to wearable microfluidic sweat sensing patent landscape, with the prior art for and against each one.
The dataset points to a field with a crowded diagnostic-hardware core and several thinner branches worth a closer look before committing a filing strategy.
The claim overlap between top-5 assignees and the most-cited foundational art is dense in A61B and G01N. Before drafting new claims in those subclasses, check the specific material, geometry, or fabrication limitations that separate a workable filing from existing coverage.
Explore claim scope in Eureka →A61N and A61M claims remain under 4% of the 855 records each. Track new filings in these subclasses closely, since a small number of early movers could establish broad claims in currently open space.
Monitor emerging filings in Eureka →Publication lag means the last two years of the filing trend will keep rising. Re-run this analysis in a future cycle to see whether the 2021-2024 growth rate holds once those years are complete.
Set a tracking alert in Eureka →The assignee ranking covers 100 companies across the 855 records in scope, with the leader holding 44 records and the fifth-place holder 30. The top 5 combined account for 22.6% of all 855 records, and the top 10 combined reach 36.5%, so filing is concentrated at the top but far from monopolised. Beyond the ranked leaders sits a long tail of entrants filing only a handful of records each, which is typical for a field still adding new technical routes rather than converging on one design.
A61B (diagnosis and surgery) is the dominant subclass, appearing in 78.1% of the 855 records, reflecting the field's core focus on skin-contact sensing hardware. G01N (material analysis and testing) follows at 33.5%, covering the assay chemistry behind the readings. Smaller but notable shares sit in G16H healthcare informatics (10.1%) and C12Q enzyme/DNA measurement (8.8%), pointing to a data-interpretation layer that is growing but still much thinner than the core sensing claims.
Yes, based on the complete years available: filings rose from 60 in 2021 to 77 in 2024, a 28% increase over that span, with a peak of 124 records in 2025. Because patent publication lags filing by roughly 18 months, the 2025 and 2026 figures shown in the trend are still incomplete and will rise as more records publish. The honest read is steady growth through the last fully-settled year, not a plateau.
US20250068241A1, filed by California Institute of Technology and published 2025-02-27, claims a 3D-printed epidermal wearable microfluidic electronic skin that integrates nanomaterial/polymer/hydrogel layers with sensors, electrodes, microfluidics and an onboard processor for combined molecular and physiological health monitoring. It does not block sweat sensing or microfluidic patches generally, since both are well populated in prior art. It does narrow the specific combination of single-substrate 3D-printed fabrication with simultaneous multimodal sensing and on-device machine-learning analysis, which is the element a competing filing needs to design around.
The thinnest subclasses relative to the 855-record base are A61N electrotherapy claims (3.4%) and A61M body-fluid device claims (2.9%), both far below the dominant A61B and G01N sensing claims. That gap suggests closed-loop designs, where a sweat-analyte reading directly triggers a therapeutic or drug-delivery response on the same wearable, are still lightly claimed. Filers targeting that combination, anchored to specific channel geometry and trigger logic rather than the sensing concept alone, are more likely to clear the crowded core claims held by the ranked leaders.
Go past this page: query the whole wearable microfluidic sweat sensing patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page